We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Specialized White Blood Cells Prove Biomarkers for Diabetes Progression

By LabMedica International staff writers
Posted on 26 Aug 2019
Researchers have found that a specialized class of circulating white blood cells (CXCR5−PD-1hi Tph cells) are associated with progression for autoantibody positivity to clinical type I diabetes and have the potential to serve as biomarkers to monitor progression of this disease.

Type I diabetes is preceded by a period of asymptomatic autoimmunity characterized by positivity for pancreatic islet autoantibodies. More...
Therefore, T helper cell responses that induce B-cell activation are likely to play a critical role in the disease process.

To better understand the role of B-cell activation in type I diabetes, investigators at the University of Eastern Finland (Kuopio, Finland) aimed to evaluate the role of a recently described subset, C-X-C motif chemokine receptor type 5-negative, programmed cell death protein 1-positive (CXCR5−PD-1hi) peripheral T helper (Tph) cells, in human type I diabetes. C-X-C chemokine receptor type 5 (CXC-R5) is a G protein-coupled seven transmembrane receptor for chemokine CXCL13 (also known as BLC) and belongs to the CXC chemokine receptor family. It enables T-cells to migrate to lymph node B- cell zones.

Previous studies had found that the appearance of autoantibodies before clinical diabetes was caused by follicular helper T-cell activation of B-cells against proteins in the pancreatic islets. Peripheral helper T-cells (Tph) resemble follicular helper T-cells, but they express receptors that enable them to migrate to inflamed tissues.

For the current study, the investigators utilized samples from the Finnish DIPP (Type I Diabetes Prediction and Prevention) study in which the development of type I diabetes was followed from birth in children with genetic risk for the disease.

The frequencies of circulating CXCR5−PD-1hi T cells were analyzed by multicolor flow cytometry in a cohort of 44 children with newly diagnosed type I diabetes, 40 autoantibody-positive (AAb+) at-risk children, and 84 autoantibody-negative healthy control children. The findings were subsequently replicated in a separate cohort of 15 children with newly diagnosed type I diabetes and 15 healthy control children.

Results revealed that the frequency of circulating Tph cells was increased in children with newly diagnosed type I diabetes, especially in those who were positive for multiple autoantibodies. Importantly, circulating Tph cells were also increased in autoantibody-positive at-risk children who later progressed to type I diabetes.

"Based on our results, it is possible that peripheral helper T-cells may have a role in the development of type I diabetes. This information could be employed in the development of better methods to predict type I diabetes risk and new immunotherapies for the disease. However, more studies need to be conducted to verify our results and to further characterize the functionality of peripheral helper T- cells," said first author Ilse Ekman, a doctoral research student at the University of Eastern Finland.

The study was published in the September 2019 issue of the journal Diabetologia.

Related Links:
University of Eastern Finland


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more

Industry

view channel
Im

Eurobio Scientific Completes Acquisition of CareDx Lab Products Division

Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.